Dina Villanueva-García, Alicia Elizabeth Robledo-Galván, Cesar Adrian Martinez-Longoria, Martha Lucía Granados-Cepeda, Daniel Octavio Pacheco-Rosas, Martha Cecilia Guerrero-Almeida, Claudia Del Carmen López-Enriquez, Ricardo Stanley Vega-Barrientos, Emilia Josefina Patiño-Bahena, Martha Josefina Avilés-Robles, Guillermo Ruiz Palacios Y Santos, Daniel Ibarra-Rios, Alejandro Ernesto Macías-Hernández, Pedro Antonio Martinez-Arce, Martha Eugenia Valdivia-Proa, Esteban González-Díaz, Gilberto Tena- Alavez, Rodolfo Norberto Jiménez-Juárez, Gerardo Martinez-Aguilar, Eric Ochoa Hein, Maria Guadalupe Miranda-Novales, Daniel E Noyola, Rosa Maria Wong-Chew, Fortino Solórzano-Santos, Diana Vilar-Compte, Sarbelio Moreno-Espinosa, Francisco Javier Espinosa-Rosales, Patricia Cornejo-Juarez, Arturo Galindo-Fraga
Journal: Archives of medical research 2025;56(4):103183
PMID: 39983633
BACKGROUND
Respiratory syncytial virus (RSV) is a common cause of respiratory illness in children and adults in Latin America and Mexico. RSV circulates with seasonal peaks in fall and winter. Individuals at highest risk for severe infection are premature infants and those with comorbidities, as well as older adults with cardiopulmonary pathologies and/or varying degrees of immunocompromise.
OBJECTIVE
To provide an updated landscape of the epidemiology, risk groups, diagnostic methods, and prevention of RSV infection in Mexico.
METHODS
Convened by the Asociación Mexicana de Infectología y Microbiología Clínica, 28 interdisciplinary experts participated in a consensus meeting held in November 2023. Four groups, each with seven experts and a medical writer, were formed to discuss epidemiology and diagnosis, risk groups, vaccines, and monoclonal antibodies (mABs). Predefined questions, formulated by a team of four experts, were discussed within each group, and consensus was reached on the answers. These responses were then analyzed and organized into recommendations based on national and international evidence.
RESULTS
Evidence-based recommendations for epidemiological surveillance, diagnosis, and prevention of RSV infection were proposed. Future perspectives regarding the usefulness of new vaccines and passive immunoprophylaxis were analyzed.
CONCLUSIONS
Timely identification of at-risk populations, diagnosis and treatment of RSV infection, and particularly the rational use of mABs and vaccines are key strategies to reduce the clinical and epidemiological burden of RSV infection.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Full Text Sources:
Medical:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.